PRAMEF6 Inhibitors
PRAMEF6 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of PRAMEF6, a member of the Preferentially Expressed Antigen in Melanoma Family (PRAME). PRAMEF6, like other PRAME family proteins, is believed to regulate gene expression by interacting with transcriptional machinery, influencing cellular processes such as proliferation, differentiation, and survival. Although the precise biological role of PRAMEF6 remains less characterized, it likely functions in transcriptional repression or activation, modulating the expression of genes involved in key cellular pathways. PRAMEF6 may contribute to maintaining cellular homeostasis and regulating how cells respond to environmental signals or developmental cues. Inhibiting PRAMEF6 allows researchers to disrupt these regulatory mechanisms, providing insights into the specific functions of PRAMEF6 in gene regulation and cellular function.
In research, PRAMEF6 inhibitors serve as valuable tools for exploring the molecular mechanisms by which PRAMEF6 influences transcriptional regulation and how it impacts cellular processes. By blocking PRAMEF6 activity, scientists can study the downstream effects on gene expression, particularly focusing on how the absence of PRAMEF6 impacts cellular behaviors such as growth, differentiation, and apoptosis. This inhibition offers the opportunity to investigate how PRAMEF6 interacts with other transcriptional regulators or signaling proteins and the consequences of these interactions on cell cycle progression and other critical pathways. Additionally, PRAMEF6 inhibitors provide insights into the broader role of PRAMEF6 in cellular adaptation and stress responses, shedding light on how this protein contributes to maintaining cellular stability under various conditions. Through these studies, the use of PRAMEF6 inhibitors enhances our understanding of the PRAME family's role in transcriptional control and the complex networks that regulate cellular function and gene expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This agent could induce DNA hypomethylation at the PRAMEF6 gene's promoter region, potentially leading to the suppression of its transcription in melanoma cells. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid may increase histone acetylation levels, leading to a tighter chromatin structure around the PRAMEF6 gene, thereby silencing its expression in tumor cells. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
By demethylating cytosines in the DNA sequence of the PRAMEF6 gene promoter, 5-Aza-2′-Deoxycytidine could diminish its transcriptional activity in cancerous tissues. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid could inhibit the expression of PRAMEF6 by antagonizing transcription factors bound to its enhancer regions in differentiated cells. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone may repress PRAMEF6 transcription by activating glucocorticoid response elements that lead to transcriptional interference at the PRAMEF6 locus. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide could inhibit heat shock proteins that are necessary for the stability of transcriptional machinery at the PRAMEF6 gene, thus decreasing its expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin may obstruct the mTOR pathway, which is crucial for cap-dependent translation initiation; this could reduce the overall protein levels of PRAMEF6. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin could decrease PRAMEF6 expression by disrupting the interaction between hypoxia-inducible factor 1-alpha and coactivators at the PRAMEF6 promoter under hypoxic conditions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may inhibit the MEK/ERK pathway, leading to decreased phosphorylation and activation of transcription factors that drive PRAMEF6 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 could block PI3K signaling, which is often upstream of transcriptional control mechanisms, potentially leading to reduced expression of PRAMEF6. | ||||||